Study on SRL172 and Chemotherapy for Lung Cancer
Author Information
Author(s): O’Brien M E R, Saini A, Smith I E, Webb A, Gregory K, Mendes R, Ryan C, Priest K, Bromelow K V, Palmer R D, Tuckwell N, Kennard D A, Souberbielle B E
Primary Institution: Royal Marsden Hospital NHS Trust
Hypothesis
Does combining SRL172 with chemotherapy improve outcomes for patients with advanced inoperable non-small-cell lung cancer and mesothelioma?
Conclusion
The combination of SRL172 with chemotherapy may improve response rates and survival in patients with advanced lung cancer and mesothelioma.
Supporting Evidence
- The toxicity of chemotherapy was similar in both treatment groups.
- Patients receiving SRL172 had a trend towards improved response rates.
- Median survival was longer in the SRL172 group compared to chemotherapy alone.
- One-year survival rates were higher in the group receiving SRL172.
Takeaway
This study tested a new treatment for lung cancer using a vaccine and chemotherapy, and it seems to help some patients live longer.
Methodology
Patients were randomized to receive either chemotherapy alone or chemotherapy with SRL172, and outcomes were measured by survival and tumor response.
Participant Demographics
Patients with previously untreated symptomatic NSCLC and mesothelioma.
Statistical Information
P-Value
P = 0.01
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website